Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2025, Vol. 57 ›› Issue (3): 599-603. doi: 10.19723/j.issn.1671-167X.2025.03.026

Previous Articles     Next Articles

Predictors of adverse pregnancy outcomes in patients with systemic lupus erythematosus

Wenqiong WANG, Yuke HOU, Chun LI*(), Xuewu ZHANG*()   

  1. Department of Rheumatology and Immunology, Peking University People' s Hospital, Beijing 100044, China
  • Received:2022-09-01 Online:2025-06-18 Published:2025-06-13
  • Contact: Chun LI, Xuewu ZHANG
  • Supported by:
    China International Medical Foundation(Z-2018-40-2101)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To identify predictors of adverse pregnancy outcomes (APOs) in patients with systemic lupus erythematosus (SLE). Methods: A retrospective analysis was conducted on 318 SLE patients who delivered at Peking University People' s Hospital from May 2016 to September 2021. These patients were categorized into two groups The APOs group (n=85) and the non-APOs group (n=233). Various factors, including disease duration, clinical manifestations, laboratory parameters, and systemic lupus erythematosus disease activity index 2000 (SLEDAI-2000) scores, were analyzed for their association with APOs. SPSS 26.0 software was used to analyze the data. Results: The mean age of SLE patients in this study was (24.65±5.26) years. Among the 318 pregnancies studied, 302 (302/318, 94.97%) resulted in live births, while 16 (16/318, 5.03%) cases ended in stillbirths, with no neonatal deaths reported. Among the live births, 206 (206/302, 68.21%) were full-term infants, 65 (65/302, 21.52%) cases were small for gestational age (SGA), and 31 (31/302, 10.26%) cases were preterm. The SLEDAI-2000 scores were significantly higher in the APOs group compared with the non-APOs group (5.82±4.97 vs. 3.74±3.72, t=4.019, P=0.001), suggesting greater disease activity as a risk factor. Similarly, glucocorticoid doses were markedly higher in the APOs group [12.50 (7.50, 50.00) mg vs. 10.00 (5.00, 15.00) mg, P < 0.001], underscoring the link between disease severity and APOs. Univariate analysis revealed that lupus nephritis (31.76% vs. 21.03%, χ2=3.946, P=0.047), thrombocytopenia (24.71% vs. 9.01%, χ2=13.380, P < 0.001), hypocomplementemia (36.47% vs. 26.03%, χ2=4.847, P=0.028), antiphospholipid antibody positivity (20.00% vs. 11.16%, χ2=4.163, P=0.041), and absence of pregnancy treatment (21.18% vs. 11.59%, χ2=4.713, P=0.030) were associated with increased APOs risk. Multivariate Logistic regression identified thrombocytopenia (OR=2.671, 95%CI 1.309-5.449, P=0.007), hypocomplementemia (OR=1.935, 95%CI 1.104-3.393, P=0.021), and antiphospholipid antibody positivity (OR=2.153, 95%CI 1.054-4.399, P=0.035) as independent predictors of APOs. Conclusion: These findings highlight that certain clinical and laboratory features, including thrombocytopenia, hypocomplementemia, and antiphospholipid antibody positivity, are critical independent predictors of APOs in SLE patients. The study underscores the importance of close monitoring and proactive management of these risk factors to improve pregnancy outcomes in SLE patients.

Key words: Systemic Lupus Erythematosus, Adverse pregnancy outcomes, Predictors

CLC Number: 

  • R593.2

Table 1

Comparison of clinical and laboratory characteristics between patients with or without APOs"

Items APOs group (n=85) Non-APOs group (n=233) t/χ2 P
Age at diagnosis of SLE/years, $\bar x \pm s$ 24.20±5.36 24.96±5.20 1.262 0.208
Disease duration/years, $\bar x \pm s$ 8.59±6.00 7.35±4.56 1.028 0.307
Clinical manifestations
    Malar rash, n (%) 23 (27.06) 60 (25.75) 0.055 0.814
    Photosensitivity, n (%) 8 (9.41) 18 (7.73) 0.236 0.627
    Oral ulcers, n (%) 5 (5.88) 7 (3.00) 1.421 0.233
    Fever, n (%) 24 (28.24) 61 (26.18) 0.134 0.714
    Arthritis, n (%) 21 (24.71) 54 (23.18) 0.081 0.776
    Myositis, n (%) 2 (2.35) 8 (3.43) 0.239 0.625
    Serositis, n (%) 4 (4.71) 11 (4.72) 0 >0.999
    Vasculitis, n (%) 2 (2.35) 1 (0.43) 2.466 0.116
    LN, n (%) 27 (31.76) 49 (21.03) 3.946 0.047*
    NPSLE, n (%) 3 (3.53) 7 (3.00) 0.056 0.812
    Haematologic disorder, n (%) 46 (54.12) 92 (39.48) 5.429 0.020*
Laboratory indexes
    Leukopenia, n (%) 10 (11.76) 34 (14.59) 0.418 0.518
    Anemia, n (%) 30 (35.29) 62 (26.61) 2.285 0.131
    Thrombocytopenia, n (%) 21 (24.71) 21 (9.01) 13.38 < 0.001*
    Hypocomplementemia, n (%) 31 (36.47) 56 (26.03) 4.847 0.028*
    Anti-dsDNA positivity, n (%) 20 (23.53) 42 (18.03) 1.202 0.273
    Antiphospholipid antibodies positivity, n (%) 17 (20.00) 26 (11.16) 4.163 0.041*
SLEDAI-2000, $\bar x \pm s$ 5.82±4.97 3.74±3.72 4.019 0.001*
1
Petri M . Pregnancy and systemic lupus erythematosus[J]. Best Pract Res Clin Obstet Gynaecol, 2020, 64 (3): 24- 30.
2
中国系统性红斑狼疮研究协作组专家组, 国家风湿病数据中心. 中国系统性红斑狼疮患者围产期管理建议[J]. 中华医学杂志, 2015, 95 (14): 1056- 1060.

doi: 10.3760/cma.j.issn.0376-2491.2015.14.005
3
张学武. 系统性红斑狼疮患者的妊娠及用药[J]. 中国临床医生杂志, 2015, 43 (7): 19- 21.

doi: 10.3969/j.issn.2095-8552.2015.07.007
4
Hamijoyo L , Martha JW , Hidayat S , et al. Risk factors for poor pregnancy outcome in systemic lupus erythematosus patients[J]. Acta medica Indonesiana, 2019, 51 (2): 102- 109.
5
Nakai T , Kitada A , Fukui S , et al. Risk of adverse pregnancy outcomes in Japanese systemic lupus erythematosus patients with prior severe organ manifestations: A single-center retrospective analysis[J]. Lupus, 2021, 30 (9): 1415- 1426.

doi: 10.1177/09612033211016074
6
Fava A , Petri M . Systemic lupus erythematosus: Diagnosis and clinical management[J]. J Autoimmun, 2019, 96 (1): 1- 13.
7
Yelnik CM , Laskin CA , Porter TF , et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: Validation of PROMISSE study results[J]. Lupus Sci Med, 2016, 3 (1): e000131.

doi: 10.1136/lupus-2015-000131
8
Kim MY , Buyon JP , Guerra MM , et al. Angiogenic factor imba-lance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study[J]. Am J Obstet Gynecol, 2016, 214 (1): 108.e1- 108.e14.

doi: 10.1016/j.ajog.2015.09.066
9
Kaul A , Gordon C , Crow MK , et al. Systemic lupus erythematosus[J]. Nat Rev Dis Primers, 2016, 2, 16039.

doi: 10.1038/nrdp.2016.39
10
Velo-García A , Castro SG , Isenberg DA . The diagnosis and management of the haematologic manifestations of lupus[J]. J Autoimmun, 2016, 74 (9): 139- 160.
11
Artım-Esen B , Çene E , Șahinkaya Y , et al. Autoimmune haemolytic anaemia and thrombocytopaenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: Clinical associations and effect on disease damage and survival[J]. Lupus, 2019, 28 (12): 1480- 1487.

doi: 10.1177/0961203319877245
12
Shi H , Chen L , Wang Y , et al. Severity of anemia during pregnancy and adverse maternal and fetal outcomes[J]. JAMA Netw Open, 2022, 5 (2): e2147046.

doi: 10.1001/jamanetworkopen.2021.47046
13
Lin L , Wei Y , Zhu W , et al. Prevalence, risk factors and associated adverse pregnancy outcomes of anaemia in Chinese pregnant women: A multicentre retrospective study[J]. BMC Pregnancy Childbirth, 2018, 18 (1): 111.

doi: 10.1186/s12884-018-1739-8
14
Venkatachala RP , Sheela CN , Anandram S , et al. Autoimmune hemolytic anaemias in pregnancy: Experience in a Tertiary Care Hospital in South India[J]. J Obstet Gynaecol India, 2021, 71 (4): 379- 385.

doi: 10.1007/s13224-021-01443-8
15
Laužikien D , Ramašauskait D , Lūža T , et al. Pregnancy induced autoimmune warm antibodies hemolytic anemia: A case report[J]. Geburtshilfe Frauenheilkd, 2015, 75 (11): 1167- 1171.

doi: 10.1055/s-0035-1558131
16
Chapin J , Terry HS , Kleinert D , et al. The role of complement activation in thrombosis and hemolytic anemias[J]. Transfus Apher Sci, 2016, 54 (2): 191- 198.

doi: 10.1016/j.transci.2016.04.008
17
Thornton P , Douglas J . Coagulation in pregnancy[J]. Best Pract Res Clin Obstet Gynaecol, 2010, 24 (3): 339- 352.

doi: 10.1016/j.bpobgyn.2009.11.010
18
Laude I , Rongières-Bertrand C , Boyer-Neumann C , et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: A new insight[J]. Thromb Haemost, 2001, 85 (1): 18- 21.

doi: 10.1055/s-0037-1612657
19
Ushida T , Kotani T , Moriyama Y , et al. Platelet counts during normal pregnancies and pregnancies complicated with hypertensive disorders[J]. Pregnancy Hypertens, 2021, 24 (2): 73- 78.
20
Subtil S FC , Mendes JMB , Areia ALFD , et al. Update on thrombocytopenia in pregnancy[J]. Rev Bras Ginecol Obstet, 2020, 42 (12): 834- 840.

doi: 10.1055/s-0040-1721350
21
Reese JA , Peck JD , Deschamps DR , et al. Platelet counts during pregnancy[J]. N Engl J Med, 2018, 379 (1): 32- 43.

doi: 10.1056/NEJMoa1802897
22
Liu J , Zhao Y , Song Y , et al. Pregnancy in women with systemic lupus erythematosus: A retrospective study of 111 pregnancies in Chinese women[J]. J Matern Fetal Neonatal Med, 2012, 25 (3): 261- 266.

doi: 10.3109/14767058.2011.572310
23
Nalli C , Lini D , Andreoli L , et al. Low preconception complement levels are associated with adverse pregnancy outcomes in a multicenter study of 260 pregnancies in 197 women with antiphospholipid syndrome or carriers of antiphospholipid antibodies[J]. Biomedicines, 2021, 9 (6): 671.
24
Girardi G , Yarilin D , Thurman J M , et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction[J]. J Exp Med, 2006, 203 (9): 2165- 2175.
25
Buyon JP , Kim MY , Guerra MM , et al. Predictors of pregnancy outcomes in patients with lupus[J]. Ann Intern Med, 2015, 163 (3): 153- 163.
26
Smyth A , Oliveira GHM , Lahr BD , et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis[J]. Clin J Am Soc Nephrol, 2010, 5 (11): 2060- 2068.
27
Hladunewich MA . Chronic kidney disease and pregnancy[J]. Semin Nephrol, 2017, 37 (4): 337- 346.
28
Stern C , Chamley L . Antiphospholipid antibodies and coagulation defects in women with implantation failure after IVF and recurrent miscarriage[J]. Reprod BioMed Online, 2006, 13 (1): 29- 37.
29
Saccone G , Berghella V , Maruotti GM , et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: The PREGNANTS study[J]. Am J Obstet Gynecol, 2017, 216 (5): 525.el- 525.e12.
30
de Carolis S , Tabacco S , Rizzo F , et al. Antiphospholipid syndrome: An update on risk factors for pregnancy outcome[J]. Autoimmun Rev, 2018, 17 (10): 956- 966.
31
Andreoli L , Bertsias GK , Agmon-Levin N , et al. EULAR recommendations for women' s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome[J]. Ann Rheum Dis, 2017, 76 (3): 476- 485.
[1] Hongyan WANG, Xinming LI, Kechi FANG, Huaqun ZHU, Rulin JIA, Jing WANG. Analysis of characteristics related to the disease activity of systemic lupus erythematosus and construction of an evaluation model [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1017-1022.
[2] Dandan CHEN, Yun LI, Qingyi LU, Xiaohong XIANG, Feng SUN, Yingni LI, Jing ZHAO, Hongyan WANG, Chun LI. Ovarian function in patients of childbearing age with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1023-1028.
[3] Li WANG, Chao GAO, Huanhuan REN, Yanping SHEN, Xiaowei HUANG, Hong YAO, Dandan HAN. Current status and influential factors of self-management ability in patients with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1029-1035.
[4] Jing CHAI, Yue WANG, Rong MU, Jinxia ZHAO. Systemic lupus erythematosus involving the fornix column leading to hyponatremia: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1115-1118.
[5] Mingxia WANG, Ling DING, Min WANG, Chanjuan ZOU, Siyu YAN, Yingwen LIANG, Weijia WANG, Shanzhi HE. Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1119-1125.
[6] Zhihui WU, Mingzhi HU, Qiaoying ZHAO, Fengfeng LV, Jingying ZHANG, Wei ZHANG, Yongfu WANG, Xiaolin SUN, Hui WANG. Immunomodulatory mechanism of umbilical cord mesenchymal stem cells modified by miR-125b-5p in systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 860-867.
[7] Limin REN,Chuchu ZHAO,Yi ZHAO,Huiqiong ZHOU,Liyun ZHANG,Youlian WANG,Lingxun SHEN,Wenqiang FAN,Yang LI,Xiaomei LI,Jibo WANG,Yongjing CHENG,Jiajing PENG,Xiaozhen ZHAO,Miao SHAO,Ru Li. Low disease activity and remission status of systemic lupus erythematosus in a real-world study [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 273-278.
[8] Hai-hong YAO,Fan YANG,Su-mei TANG,Xia ZHANG,Jing HE,Yuan JIA. Clinical characteristics and diagnostic indicators of macrophage activation syndrome in patients with systemic lupus erythematosus and adult-onset Still's disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 966-974.
[9] Zhi-jun LUO,Jia-jia WU,You SONG,Chun-li MEI,Rong DU. Systemic lupus erythematosus associated macrophage activation syndrome with neuropsychiatric symptoms: A report of 2 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1111-1117.
[10] Fang-ning YOU,Liang LUO,Xiang-jun LIU,Xue-wu ZHANG,Chun LI. Analysis of pregnancy outcomes, disease progression, and risk factors in patients with undifferentiated connective tissue disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1045-1052.
[11] Xiang-ge ZHAO,Jia-qing LIU,Hui-na HUANG,Zhi-min LU,Zi-ran BAI,Xia LI,Jing-jing QI. Interferon-α mediating the functional damage of CD56dimCD57+natural killer cells in peripheral blood of systemic lupus erythematosuss [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 975-981.
[12] Miao SHAO,Hui-fang GUO,Ling-yan LEI,Qing ZHAO,Yan-jie DING,Jin LIN,Rui WU,Feng YU,Yu-cui LI,Hua-li MIAO,Li-yun ZHANG,Yan DU,Rui-ying JIAO,Li-xia PANG,Li LONG,Zhan-guo LI,Ru LI. A multicenter study on the tolerance of intravenous low-dose cyclophosphamide in systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1112-1116.
[13] Min LI,Lin-qing HOU,Yue-bo JIN,Jing HE. Clinical and immunological characteristics of systemic lupus erythematosus with retinopathy [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1106-1111.
[14] Lin-qi ZHANG,Jing ZHAO,Hong-yan WANG,Zong-yi WANG,Ying-ni LI,Ji-yang TANG,Si-ying LI,Jin-feng QU,Ming-wei ZHAO. Relationship between anti-ENO1 antibody and systemic lupus erythematosus patients with retinopathy [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1099-1105.
[15] Jian-mei ZOU,Li-jun WU,Cai-nan LUO,Ya-mei SHI,Xue WU. Relationship of serum 25- hydroxy vitamin D and systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 938-941.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd